News

Wednesday, 16. May 2012

Antisense Pharma presents clinical data at ASCO in Chicago, USA

On June 4th Antisense Pharma presents final results of a clinical Phase I/II study with trabedersen in patients with malignant melanoma, pancreatic cancer and colorectal cancer.  mehr

Thursday, 10. May 2012

Antisense Pharma Internationalizes Management Board

Antisense Pharma announces the appointment of Dr. Philippe Calais as CEO. The native-born Frenchman has more than two decades of international experience in executive positions in biotech and pharmaceutical companies  mehr

Monday, 16. April 2012

Antisense Pharma presents at DIA/FDA meeting in Washington, DC

Dr. Hubert Heinrichs presents clinical data on trabedersen during the session "Trabedersen is highly effective against TGF-β2 and shows high efficacy and tolerability in several cancer indications" on April 16th.  mehr

Thursday, 01. March 2012

Antisense Pharma with new Chief Executive Officer (CEO)

Dr. Philippe Calais, international expert for drug commercialization, was appointed as CEO. Dr. Hubert Heinrichs (CMO) held the position as Acting-CEO since July last year. more

Saturday, 04. February 2012

German Science Day: Germany Leads Europe in the Fight Against Cancer

Leading German biotechnology companies working on cancer presented their major research and development results. Antisense Pharmas session introducing the promissing approach with trabedersen can be looked up here more